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In Argentina, the public health system is deeply decentralized and
organized mainly at the provincial level. In this context, differ-
ences regarding income distribution and access to health services
require the creation of regulatory devices and state intervention,
the public health system is deeply decentralized and organized
mainly at the provincial level. In this context, differences regarding
income distribution and access to health services require the
creation of regulatory devices and state intervention. One of
the answers provided by the Buenos AiresHealthMinistrywas the
creation of a Provincial Public Health Insurance, aimed at guar-
antying access and quality health services to population without
formal health coverage and economic resources to afford one. This
program included an innovative mechanism of human resources
payment for the public sector—a capitated system with the pos-
sibility to generate a plus over the ﬁxed salary- and aimed to reach
the coverage of 2.4 million citizens.OBJECTIVES: To analyze the
performance of the strategy in terms of focalization and develop-
ment of preventive tasks associated with higher quality at the
primary health care level. METHODS: A database of 1.7 million
of consultations in 59 municipalities during the period 2004 to
2006 was analyzed, considering the evolution of preventive and
curative consultations. Logistic regression models were imple-
mented to determine the variables conditioning those tendencies
(patient age and sex, physicians’ expertise, poverty, population
density and health expenditure by municipality, among others).
RESULTS: The program was appropriately focalized in poor
municipalities. Preventive consultations increased 107% during
the three year period, and curative consultations decreased by
56%. Preventive consultations were signiﬁcantly associated with
young and female patients, as well as younger physicians. Also,
poor and populated municipalities showed high associations with
preventive consultations. Differences betweenmunicipalities were
relevant, showing signiﬁcant associations on both sides. CON-
CLUSIONS: The insurance’s hiring and payment mechanisms,
results were innovative and successful in the public health sub-
sector, causing the professionals to increase their efforts towards
higher quality preventive care. The strategy might be seen as one
of the instruments with the potential to enhance care, quality
and performance. Nevertheless, municipalities show particular
characteristics regarding their management and administrative
structures that affect the success of the program.
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OBJECTIVES: To document patterns in EMEA and FDA
approved product label claims based on patient self-report data
before and after publication of the 2005 EMEA Reﬂection Paper
on Health-related Quality of Life (HRQL) and FDA’s draft guid-
ance on Patient Reported Outcome Measures: Use in Medical
Product Development to Support Labeling Claims. METHODS:
PRO claims for products approved between January 2000 and
June 2008 were identiﬁed from review of the PROQOLID data-
base. Analyses compared FDA and EMEA claims for the same
product to document patterns in the number and types of claims
approved, and to determine whether the nature of claims reﬂect
recent FDA and EMEA guidance on review of PRO and HRQL
data. RESULTS: More PRO-based claims were approved by
FDA than EMEA (147 vs. 77) during the 9 year period. Of these,
only 27 were for the same product reviewed and approved by
both agency. PRO-based claims usually involved symptoms
(FDA = 127, 86%; EMEA = 53, 69%). EMEA approved more
claims for improvement in HRQL than did FDA (EMEA = 31;
FDA = 11). Nine of 31 (29%) of EMEA approved HRQL claims
were granted since the publication of the EMEA Reﬂection
paper; compared with 45% (5 of 11) of FDA-approved HRQL
claims granted since the draft FDA PRO guidance was issued.
CONCLUSIONS: Despite concerns that PRO and HRQL claims
would be less common after issuance of these guidance docu-
ments, approvals to date suggests that PRO continue to be criti-
cal for symptom claims and HRQL claims continue to be granted
by both agencies. Clinician-reported symptom assessments may
explain some differences in symptom claims.
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OBJECTIVES: To compare the health economic guidelines of the
Czech Republic, Hungary, Poland and Slovak Republic (so-called
Visegrad countries) and to evaluate the similarities and differ-
ences between them. METHODS: We have searched the local
ISPOR chapters and reimbursement bodies in every country to
obtain the up-to-date version of health economic/pharmaco-
economic guidelines. The guidelines were summarised in a table
format and 24 methodological aspects were evaluated.
RESULTS: All guidelines had recommendatory status and were
published between 2000 and 2006. A level of agreement between
the guidelines was in 11 following aspects—description of health
care intervention, target population, subgroup analysis, choice of
treatment comparator, time horizon, assumptions required,
source of costs used in the analysis, modelling, preference of
effectiveness over efﬁcacy, incremental analysis and the way of
reporting results. Disagreement between guidelines was found in
choice of perspective, preferred analytical technique, costs to be
included, discounting of future costs and outcomes. The pre-
ferred analytical technique and transferability of results were
clearly stated only in Hungarian and Polish guidelines. The
Slovak guidelines varied from the others in outcome measure-
ment and preferred method to derive utility. The following
aspects were explored not to be included in the Czech
guidelines—systematic review of evidence, sensitivity analysis
and its parameters, range and methods, total cost-effectiveness,
ﬁnancial impact analysis and standard reporting form. CON-
CLUSIONS: This review discovered that the Czech, Hungarian,
Polish and Slovak pharmacoeconomic guidelines were consistent
in about half of the methodological aspects. The Czech guidelines
were missing crucial aspects thus further research should be done
to facilitate the harmonisation with the other guidelines of the
Visegrad countries.
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